Gout and hyperuricaemia: modifiable cardiovascular risk factors?
M Burnier - Frontiers in Cardiovascular Medicine, 2023 - frontiersin.org
Gout and hyperuricaemia are two clinical situations associated with an elevated risk of
developing cardiovascular (heart failure, myocardial infarction, stroke) and metabolic and …
developing cardiovascular (heart failure, myocardial infarction, stroke) and metabolic and …
Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis
Purpose To collate the effect of SGLT2 inhibitors (SGLT2i) on adverse gout events in people
with type 2 diabetes mellitus (T2DM). Methods PubMed/MEDLINE, Embase, and Web of …
with type 2 diabetes mellitus (T2DM). Methods PubMed/MEDLINE, Embase, and Web of …
Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes
J Wei, HK Choi, N Dalbeth, X Li, C Li, C Zeng… - JAMA Network …, 2023 - jamanetwork.com
Importance Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-
glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a lower risk of …
glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a lower risk of …
Serum uric acid lowering and effects of sodium‐glucose cotransporter‐2 inhibitors on gout: A meta‐analysis and meta‐regression of randomized controlled trials
M Banerjee, R Pal, I Maisnam… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aims To pool the effects of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on gout and
to investigate the association of these effects with baseline serum uric acid (SUA), SUA …
to investigate the association of these effects with baseline serum uric acid (SUA), SUA …
Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis
Objective To assess the relationship between use of sodium-glucose cotransporter-2
inhibitors (SGLT2i) and the risk of gout among patients with type 2 diabetes mellitus (T2DM) …
inhibitors (SGLT2i) and the risk of gout among patients with type 2 diabetes mellitus (T2DM) …
Prescribing cascades in community‐dwelling adults: a systematic review
AS Doherty, F Shahid, F Moriarty… - Pharmacology …, 2022 - Wiley Online Library
The misattribution of an adverse drug reaction (ADR) as a symptom or illness can lead to the
prescribing of additional medication, referred to as a prescribing cascade. The aim of this …
prescribing of additional medication, referred to as a prescribing cascade. The aim of this …
Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: a multi-institutional cohort study in Taiwan
Abstract Purpose Type 2 diabetes (T2D) is an important risk factor for glaucoma, and sodium-
glucose co-transporter 2 (SGLT2) inhibitors have been shown to protect the optic nerves. We …
glucose co-transporter 2 (SGLT2) inhibitors have been shown to protect the optic nerves. We …
The mechanism of sodium-glucose cotransporter-2 inhibitors in reducing uric acid in type 2 diabetes mellitus
M Dong, H Chen, S Wen, Y Yuan, L Yang… - Diabetes, Metabolic …, 2023 - Taylor & Francis
Hyperuricemia is a common comorbidity in patients with type 2 diabetes mellitus (T2DM), as
insulin resistance (IR) or hyperinsulinemia is associated with higher serum uric acid (SUA) …
insulin resistance (IR) or hyperinsulinemia is associated with higher serum uric acid (SUA) …
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
C Yokose, N McCormick, A Abhishek… - Nature Reviews …, 2024 - nature.com
Gout is the most common form of inflammatory arthritis worldwide and is characterized by
painful recurrent flares of inflammatory arthritis that are associated with a transiently …
painful recurrent flares of inflammatory arthritis that are associated with a transiently …
SGLT2 Inhibitors–The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
S Seidu, V Alabraba, S Davies, P Newland-Jones… - Diabetes Therapy, 2024 - Springer
A substantial evidence base supports the use of sodium-glucose cotransporter-2 inhibitors
(SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has …
(SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has …